A Dengue Vaccine: Research Program is Starting
Clinical trials of a new Dengue vaccine involving 400 local citizens of 21 to 45 years are starting in Singapore. The trial is sponsored by Japanese Takeda.
Tests will involve both people that already had that dangerous illness, and those who had never been exposed to Dengue.
Note, that Dengue fever is a viral infection, predominantly endemic in tropical and subtropical regions. Its symptoms, high temperature, nausea, headache and low back pain. Hemorrhagic type fever is associated with severe internal hemorrhages due to blood vessel collapse.
Within clinical trials after vaccination volunteers will be followed up for one year by researchers who will collect information about their symptoms. It was also remarked in the corporation that the study will also compare the antibody levels produced by human body with and without vaccination.